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Background: Erythrocyte aggregation, a cardiovascular risk factor, is increased by high plasma 
fibrinogen levels. Here, the effect of different fibrinogen mutations on binding to its human eryth-
rocyte receptor was assessed in order to identify the interaction sites. 
Methods: Three fibrinogen variants were tested, specifically mutated in their putative integrin 
recognition sites on the AA chain (mutants D97E, D574E and D97E/D574E) and compared 
with wild-type fibrinogen. 
Results: Atomic force microscopy-based force spectroscopy measurements showed a significant 
decrease both on the fibrinogen–erythrocyte binding force and on its frequency for fibrinogen 
with the D97E mutation, indicating that the corresponding arginine–glycine–aspartate sequence 
(residues 95–97) is involved in this interaction, and supporting that the fibrinogen receptor on 
erythrocytes has a B
3
 subunit. Changes in the fibrin clot network structure obtained with the 
D97E mutant were observed by scanning electron microscopy. 
Conclusion: These findings may lead to innovative perspectives on the development of new ther-
apeutic approaches to overcome the risks of fibrinogen-driven erythrocyte hyperaggregation.
Keywords: atomic force microscopy, fibrinogen, fibrin clot, erythrocyte aggregation, mutant 
protein
Plain language summary
Currently, cardiovascular diseases are the leading cause of mortality worldwide, accounting 
for about one third of all deaths. Erythrocyte aggregation, which may lead to the formation of 
thrombus on the bloodstream, is associated with an increase in the concentration of fibrinogen. 
However, it is not known which binding sites on the fibrinogen protein structure are involved 
on the interaction with its specific receptor on the erythrocyte membrane, contributing to 
erythrocyte aggregation.
Here, the effect of different fibrinogen mutations on binding to its human erythrocyte 
receptor was assessed in order to identify the interaction sites. Using atomic force micros-
copy, a nanotechnology technique, we were able to use mutated fibrinogen molecules as 
“bait” to “fish” its receptor on the surface of red blood cells. It was shown that the force 
required to break the binding between fibrinogen (the “bait”) and red blood cell (the “fish”), 
as well as the frequency of this binding, were lower for the proteins with the D97E mutation 
on the AA chain, indicating that the corresponding arginine–glycine–aspartate sequence 
is involved in this interaction. Changes on fibrin clot network for the D97E mutant were 
also observed.
This study opens new perspectives on the development of novel therapeutic approaches to 
overcome the risks of fibrinogen-driven erythrocyte hyperaggregation.
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Introduction
Fibrinogen has a crucial role in blood clotting.1 The increase 
in fibrinogen plasma concentration leads to increased erythro-
cyte aggregation, one of the most important factors affecting 
blood flow and a significant cardiovascular risk factor.2 It has 
been reported that there is specific binding between fibrino-
gen and a previously unknown erythrocyte receptor.3
The fibrinogen molecule contains multiple binding 
motifs for different cellular receptors, acting as a molecular 
link between coagulation, inflammation and immunity. Par-
ticularly, fibrinogen binds to the A
IIb
B
3
 integrin on activated 
platelets, leading to the platelet aggregation necessary for 
blood coagulation.4,5 Three potential binding sites for this 
integrin on the fibrinogen molecule have been identified, 
which are structural RGD (arginine–glycine–aspartate) 
sequences on each AA chain (amino acid residues 572–574 
and 95–97) and one dodecapeptide sequence on the G chain, 
yielding a total of six potential binding sites per fibrinogen 
molecule (formed by two AA, two BB and two G chains).6
Maeda et al proposed a model for a possible location 
of the erythrocyte-binding regions of fibrinogen in its AA 
chain and tried to explain how it may affect erythrocyte 
aggregation and deformability.7 The AA 207–303 domain 
was found to include one of the possible erythrocyte-binding 
sites.7 Using atomic force microscopy (AFM)-based force 
spectroscopy measurements, we demonstrated the existence 
of a single-molecule interaction between fibrinogen and a 
receptor on the erythrocyte membrane, with a lower but 
comparable affinity relative to platelet binding.8 Fibrinogen 
binding to this receptor is inhibited by calcium depletion 
and by eptifibatide (an inhibitor considered to be specific 
for the receptor of fibrinogen on platelets, the glycoprotein 
A
IIb
B
3
), but not as strongly as the platelet receptor. The 
results from a Glanzmann thrombasthenia (a rare hereditary 
bleeding disease caused by A
IIb
B
3
 deficiency) patient showed 
an impaired fibrinogen–erythrocyte binding. Correlation 
with genetic sequencing data demonstrated that one of the 
units of the fibrinogen receptor on erythrocytes is a product 
of the expression of the B
3
 gene.8,9 To further assess the 
specificity of the fibrinogen–erythrocyte binding, as well 
as to complete its identification, we recently measured the 
inhibition of the fibrinogen–erythrocyte interaction using 
specific antibodies against integrins.10 We also demonstrated 
that younger erythrocytes bind more fibrinogen than the 
older ones, being therefore the main cells responsible for 
the cardiovascular risk associated with an increase in the 
fibrinogen content in blood.11 More recently, we showed 
that the interaction between fibrinogen and erythrocytes 
is modified in chronic heart failure (CHF) patients. The 
average force necessary to break the bond between fibrino-
gen and erythrocytes from CHF patients is higher than for 
erythrocytes from the control group.10 Also using AFM, 
we showed that increasing fibrinogen levels lead to an 
increase in erythrocyte–erythrocyte adhesion in essential 
arterial hypertension patients.12 Thus, AFM-based force 
spectroscopy is an approach with a high potential for appli-
cability on biomedical research, inclusively on the study of 
cardiovascular diseases.10–14
Here, three stable fibrinogen variants were obtained accord-
ing to previously established procedures,4,15 specifically altered 
in the described integrin binding sites on the AA chain (D97E, 
D574E and the D97E/D574E double mutant). Using these 
variants, we conducted force spectroscopy measurements to 
determine the force necessary to break the bond between each 
fibrinogen variant (attached to the AFM tip) and erythrocytes. 
For the sake of comparison, identical measurements were 
conducted with wild-type (WT) fibrinogen. The analysis of the 
structure of the fibrin fibers in the blood clot was done using 
scanning electron microscopy (SEM). The results shed light 
on which integrin binding sites of the fibrinogen molecule are 
involved on the binding to the erythrocyte receptor. Knowledge 
of these aspects may lead to innovative perspectives on the 
development of new therapeutic drugs to overcome the risks 
of fibrinogen-driven erythrocyte hyperaggregation.
Methods
)LEULQRJHQPXWDQWV
The constructs for the fibrinogen variants were produced 
as previously described.4,15 We performed DNA sequence 
analysis, constructed the expression vectors and conducted 
site-directed mutagenesis according to established proce-
dures. Briefly, baby hamster kidney cells, purchased from 
ATCC, were used to produce three stable fibrinogen mutants 
(AA chain mutants D97E, D574E and the D97E/D574E 
double mutant) and the WT fibrinogen. AA chain mutations 
have a single-nucleotide change, resulting in a codon for a dif-
ferent amino acid residue (aspartate changed to glutamate).
Erythrocyte isolation
Blood from adult healthy donors was collected into K
3
EDTA 
anticoagulant tubes with their previous written informed 
consent, following a protocol with the Portuguese Blood 
Institute (Lisbon), approved by the joint Ethics Committee 
of the Faculty of Medicine of the University of Lisbon 
and the Santa Maria Hospital. The experimental work was 
carried out in accordance with the Declaration of Helsinki 
of the World Medical Association. Erythrocytes were 
isolated from the blood samples according to established 
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procedures.8,10,11 Briefly, erythrocytes were separated from 
the other blood components by centrifugation at 200 g for 
10 min, at 10nC. Plasma and buffy-coat were removed, and 
the erythrocytes were washed three times with buffered 
saline glucose citrate (1.6 mM KH
2
PO
4
, 8.6 mM Na
2
HPO
4
, 
120 mM NaCl, 13.6 mM sodium citrate, 11.1 mM glucose, 
pH 7.3) supplemented with 1 mM CaCl
2
. Erythrocytes (0.1% 
hematocrit) were attached to a clean poly-L-lysine-treated 
glass slide after 30 min of deposition, at room temperature. 
Nonadherent cells were removed by sequential washes with 
buffer. Samples were loaded into the AFM and allowed to 
equilibrate in buffer for 15 min before force spectroscopy 
measurements.
$)0WLSIXQFWLRQDOL]DWLRQ
A previously optimized procedure was used for the covalent 
attachment of fibrinogen to the AFM tips (functionaliza-
tion) and for blood cells deposition on a solid substrate.8,10,11 
Briefly, cleaned AFM silicon nitride tips were silanized 
with 3-aminopropyl-triethoxysilane. Then, the probes were 
treated with a glutaraldehyde solution 2.5% (v/v) and finally 
immersed in a 0.5 mg/mL final concentration of fibrinogen 
(WT or mutant).
$)0EDVHGIRUFHVSHFWURVFRS\
Force spectroscopy measurements were performed on a 
NanoWizard II atomic force microscope (JPK Instruments, 
Berlin, Germany), mounted on an Axiovert 200 inverted 
optical microscope (Zeiss, Jena, Germany), using fibrinogen 
functionalized OMCL TR-400-type silicon nitride AFM tips 
(Olympus, Tokyo, Japan), as previously described.8 The 
spring constant of the tips was calibrated by the thermal 
fluctuation method, resulting in values of 19o7 mN/m. 
The applied force was adjusted to 0.8 nN before retraction. 
Molecular recognition was searched by intermittently press-
ing the cantilevers on each erythrocyte adsorbed on the glass 
slide. Data collection for each force–distance cycle was 
performed at 2 Mm/s, leading to a loading rate of 4 nN/s. 
Force curves were analyzed using the JPK image process-
ing software v. 4.2.61. For any given experiment, ^5,000 
force–distance curves were collected, analyzed and adjusted 
by polynomial fit.16 Each experiment was performed at least 
three times, each time on different blood samples and with 
different functionalized tips.
SEM
SEM was used to investigate the differences on structure of 
clots formed from WT and D97E recombinant fibrinogen, 
especially in the presence of erythrocytes.
WT or D97E recombinant fibrinogen (0.5 mg/mL final 
concentration) and CaCl
2
 (final concentration 10 mM) 
were diluted in TBS (50 mM Tris–HCl, 100 mM NaCl, 
pH 7.5) and premixed. Human thrombin (Calbiochem, 
Nottingham, UK; final concentration 1 U/mL) was then 
added to initiate clotting. The mixtures were immediately 
transferred to Eppendorf lids, which were pierced with a 
syringe to assist solvent permeation. Clots were formed 
in a moist chamber, at room temperature, for 120 min. 
Clots were then washed with saline solution to remove 
excess salt, followed by fixation in 2% (v/v) glutaralde-
hyde (120 min). Clots were further washed extensively 
with sodium cacodylate buffer and dehydrated in a series 
of increasing acetone concentrations (30%–100%). Clots 
were critical-point dried with CO
2
, mounted onto stubs 
and sputter-coated with platinum, using a Cressington 
208 HR (Watford, UK). Clots were also prepared with the 
appropriate amount of erythrocytes for a final hematocrit 
of 20%. They were observed and photographed digitally 
on at least three different areas per clot, using a scanning 
electron microscope Hitachi SU8230 FESEM (Tokyo, 
Japan), at five different magnifications (2,500r [data not 
shown], 5,000r, 10,000r [data not shown], 25,000r and 
50,000r). At least, duplicates of each type of clot were 
performed. Fiber diameters were measured from 20 ran-
dom fibers of each image in high magnification (25,000r), 
using ImageJ software (National Institutes of Health, 
Bethesda, MD, USA). Each cross-section measurement 
was performed over a single fibrin fiber and values of fiber 
diameter were extracted and averaged. All cross-section 
analysis were performed away from the branching points, 
in order to avoid biased results.
Statistical analysis
Unpaired samples Student’s t-test was used for statistical 
analysis. Differences were considered statistically significant 
for p0.05. For AFM, each experiment was performed at 
least three times, each time with different blood samples and 
with different functionalized tips. At least 15 erythrocytes 
were tested on each blood sample. For SEM, at least dupli-
cates of each type of clot were performed. Average fiber 
diameters were measured from 20 random fibers of each 
image, at high magnification (25,000r).
Results and discussion
AFM-based force spectroscopy studies, conducted at the 
single-molecule level, yielded force vs distance curves, 
acquired after the binding of mutant or WT fibrinogen to 
the receptor on erythrocytes (Figure 1A). The repeated 
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measurements of the adhesion events, as the one shown in 
Figure 1B, allowed us to build up rupture force histograms 
for each fibrinogen variant and cell population studied.
Figure 2A shows the rupture force histograms for the 
three different fibrinogen mutants and WT fibrinogen. It can 
be noticed that, in the presence of the D97E or D97E/D574E 
mutant, the histogram is shifted to lower binding forces, 
when compared with those obtained for WT fibrinogen. The 
opposite variation trend was obtained for the rupture force 
histogram of D574E, which is shifted to higher and stronger 
binding forces.
As it can be observed in Figure 2B, the average force 
necessary to break the bond between the D97E fibrinogen 
mutant (43.2o1.1 pN) or the D97E/D574E double mutant 
(49.2o0.8 pN) and erythrocytes is significantly lower than 
for WT fibrinogen (58.8o2.3 pN; p0.0001 for both pairs). 
On the other hand, the average force necessary to break 
the bond between erythrocytes and the D574E mutant 
(105.9o1.7 pN) was significantly higher than for the WT 
(p0.0001).
Decreases on the frequency (probability) of fibrinogen–
erythrocyte binding and subsequent unbinding for the D97E 
(11.4%), D574E (13.1%) or D97E/D574E (11.1%) mutants in 
comparison with the WT fibrinogen (15.9%) were observed. 
The variation of the binding frequency of the different 
mutants relative to the WT is presented in Figure 2C.
Our results indicate that the RGD sequence corresponding 
to amino acid residues 95–97 of the fibrinogen AA chain is 
involved in the binding to the erythrocyte membrane recep-
tor. It has previously been reported that this RGD sequence 
is also involved in the binding to the B
3
 subunit of the A
V
B
3
 
receptor in endothelial cells.17 These results further support 
our recent findings regarding the fibrinogen receptor on 
erythrocytes.8,10
The force necessary to break the bond between D574E 
fibrinogen and the erythrocyte membrane receptor was 
significantly higher than for WT fibrinogen, while the fre-
quency of (un)binding events for this mutant was lower. 
These apparently opposite effects might be explained by the 
location of the specific binding site. As it is located close to 
the C-terminus of the A chain, the domain may eventually 
change conformation, leading to a stabilization of the com-
plex formed upon binding to the erythrocyte receptor.
It is worth to mention that during the conversion of 
fibrinogen to fibrin, thrombin cleaves fibrinogen AA chain 
at Arg-16 and the BB chain at Arg-14, releasing the fibrino-
peptides A and B, respectively, and forming the so-called 
fibrin monomers.18,19 In the fibrinogen structure, the thrombin 
Figure 1 $)0EDVHGIRUFHVSHFWURVFRS\H[SHULPHQWVDQGIRUFH²GLVWDQFHFXUYH
Notes: (A6FKHPDWLFUHSUHVHQWDWLRQRIWKHHU\WKURF\WHVGHSRVLWHGRQDSRO\/O\VLQHFRDWHGJODVVVOLGHDQGDQ$)0WLSFKHPLFDOO\IXQFWLRQDOL]HGZLWKGLIIHUHQWÀEULQRJHQ
YDULDQWV7KHYHUWLFDOPRYHPHQWDSSURDFKLQJWKHWLSWRWKHVDPSOHXQWLOFRQWDFWHQDEOHVWKHELQGLQJRIÀEULQRJHQWRWKHHU\WKURF\WH7KHVXEVHTXHQWUHWUDFWLRQSURJUHVVHV
XQWLODFHUWDLQIRUFHDQGGLVWDQFHLVUHDFKHGDQGWKHÀEULQRJHQPROHFXOHGHWDFKHVIURPWKHHU\WKURF\WHVXUIDFH7KHXQELQGLQJIUHTXHQF\FRUUHVSRQGVWRWKHIUDFWLRQRI
WKHVHDSSURDFK²UHWUDFWLRQF\FOHVLQZKLFKELQGLQJDQGVXEVHTXHQWXQELQGLQJRFFXUB([DPSOHRIDIRUFH²GLVWDQFHFXUYH:KHQDSSURDFKLQJWKHWLSWRWKHVDPSOHUHGOLQH
WKHÀEULQRJHQPROHFXOHPD\FRQWDFWZLWKFHOOUHFHSWRUVDQGWKHELQGLQJEHWZHHQWKHPFDQRFFXU%\UHWUDFWLQJWKHWLSDZD\IURPWKHVDPSOHEOXHOLQHDVWKHFDQWLOHYHU
PRYHVXSZDUGWKHWLSEHQGVGRZQWRQHJDWLYHIRUFHYDOXHV,QVRPHVXUIDFHGLVWDQFHSRLQWWKHERQGEUHDNVDQGWKHFDQWLOHYHUMXPSVEDFNWRLWVQHXWUDOIRUFHSRVLWLRQ$WWKLV
SRLQWWKHELQGLQJIRUFHQHFHVVDU\WREUHDNWKHERQGDWWKHÀEULQRJHQVLQJOHPROHFXOHOHYHOFDQEHPHDVXUHG
Abbreviation: AFM, atomic force microscopy.
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cleavage regions are distant from the mutated regions of 
fibrinogen variants produced here. Therefore, these muta-
tions on the fibrinogen molecule do not interfere with the 
thrombin-induced conversion of fibrinogen to fibrin.
The existence of a specific binding mechanism in 
fibrinogen-induced erythrocyte hyperaggregation suggests 
the possibility of developing new treatments to decrease 
erythrocyte aggregation, therefore potentially decreasing 
cardiovascular risk. Fibrinogen is considered an independent 
risk factor on screening programs aimed at identifying indi-
viduals at high risk for cardiovascular diseases.20 Our results 
show that, in addition to the assessment of the plasma fibrino-
gen concentration itself, it may also be important to identify 
mutations in the fibrinogen molecules that may change the 
binding to erythrocytes as a risk assessment strategy.
Moreover, in order to see if this fibrinogen variant 
induces changes on the structure of the fibrin blood clot, 
SEM analysis was also performed. From the micrographs 
obtained for the D97E and WT fibrin clots, we observed that 
there were no differences in fibrin clot structure (Figure 3). 
Clots were also evaluated in the presence of 20% of eryth-
rocytes (Figure 4). The clots formed with WT fibrin have 
a more homogeneous structure than those formed with the 
D97E mutant. The D97E fibrin clots seem to have a more 
disorganized structure, with higher number of clusters that 
entrap erythrocytes. The clots appear to be more loosely 
packed, eventually leading to a higher risk of embolism. 
SEM images correlate well with the AFM data, where a 
decrease in both the binding force and the binding frequency 
were observed for this mutant, when compared with the 
WT fibrinogen.
After analyzing the SEM micrographs shown in Figures 3 
and 4, the diameters of the fibers were calculated (Figure 5). 
No differences in fiber diameter between both fibrinogen 
variants were observed in the absence of erythrocytes, but sta-
tistically significant differences were found in the presence of 
these cells. The addition of 20% of erythrocytes to the D97E 
fibrin clot caused a decrease in fiber thickness (37.7o2.0 nm 
without erythrocytes vs 18.9o1.1 nm with erythrocytes; 
p0.0001) and led to an extensive network rearrangement. 
Figure 2 $)0IRUFHVSHFWURVFRS\GDWDIRUWKHELQGLQJEHWZHHQGLIIHUHQWÀEULQRJHQYDULDQWVDQGHU\WKURF\WHV
Notes: (A5XSWXUHIRUFHKLVWRJUDPVRIWKHLQWHUDFWLRQVEHWZHHQWKHWKUHHGLIIHUHQWÀEULQRJHQPXWDQWV'('(DQG'('(OLJKWJUD\RU:7ÀEULQRJHQGDUN
JUD\DQGHU\WKURF\WHV2QWKHUXSWXUHIRUFHKLVWRJUDPVHDFKFRXQWUHSUHVHQWVDVLQJOHPROHFXOHELQGLQJEHWZHHQRQHÀEULQRJHQPROHFXOHDQGRQHRILWVFHOOUHFHSWRUV
(B$YHUDJHXQELQGLQJIRUFHRIWKHLQWHUDFWLRQV9DOXHVDUHVKRZQDVPHDQoVWDQGDUGHUURURIPHDQ6(07KHUHZHUHVWDWLVWLFDOO\VLJQLÀFDQWYDULDWLRQVp0.0001) 
RIWKHUXSWXUHIRUFHVEHWZHHQ:7ÀEULQRJHQDQGWKHWKUHHÀEULQRJHQYDULDQWVZLWKPXWDWLRQVRQWKH$AFKDLQ'('(DQG'('(C9DULDWLRQRIWKH
ÀEULQRJHQ²HU\WKURF\WHXQELQGLQJIUHTXHQF\RIWKHGLIIHUHQWÀEULQRJHQYDULDQWVUHODWLYHWR:7ÀEULQRJHQ8QELQGLQJIUHTXHQF\YDULDWLRQVZHUHFDOFXODWHGEDVHGRQWKH
UDWLREHWZHHQWKHIUHTXHQF\RIXQELQGLQJHYHQWVGHWHUPLQHGIRUWKHÀEULQRJHQPXWDQWVDQGWKHIUHTXHQF\RIXQELQGLQJHYHQWVREWDLQHGIRU:7ÀEULQRJHQ
Abbreviations:$)0DWRPLFIRUFHPLFURVFRS\:7ZLOGW\SH
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A statistically significant variation of the fibers’ diameters 
was also observed between WT fibrin and D97E fibrin, both 
in the presence of erythrocytes (30.8o1.8 nm vs 18.9o1.1 nm, 
respectively; p0.0001).
The difference in the D97E fibrin fibers’ diameter in the 
presence of erythrocytes is clear. This should be due to the 
mutant fibrin(ogen) interaction with erythrocytes, and not 
due to any difference in the polymerization of this fibrinogen 
variant itself, as the structure of the mutant fibrin without 
these cells seems the same as for the WT. Only when eryth-
rocytes are present, the clot D97E fibrin structure becomes 
different. 
The architecture of the clot may affect its stability, vis-
coelastic and mechanical properties, as well as its fibrinolytic 
characteristics.21,22 These characteristics may determine if a 
clot breaks down by fibrinolysis, or if it will lead to blood 
vessel occlusion or embolization.23 Moreover, it has been 
previously reported that tightly packed and rigid clots, with 
thinner fibers and low porosity, are less susceptible to the 
action of thrombolytic agents.24,25
This work yields valuable new information on the 
identification of the fibrinogen domains that interact with 
its erythrocyte membrane receptor, contributing to the 
erythrocyte hyperaggregation in the bloodstream induced 
by increased levels of fibrinogen. Moreover, in this study, 
AFM-based force spectroscopy demonstrated its potential 
as an important nanotechnology approach for biomedical 
research application, important to measure the interaction 
forces between fibrinogen (or other plasma proteins) and 
human blood cells. Future studies using animal models 
Figure 3 Clots made from WT (AC) or D97E (DFÀEULQRJHQPJP/LPDJHGE\VFDQQLQJHOHFWURQPLFURVFRS\
Notes:0DJQLÀFDWLRQVA, D, 5,000rB, E, 25,000rC, F, 50,000r.
Abbreviation: WT, wild-type.
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5HFHSWRUELQGLQJVLWHRQWKHÀEULQRJHQPROHFXOH
Figure 4 )LEULQFORWVIRUPHGLQWKHSUHVHQFHRIHU\WKURF\WHVZLWK:7AC) or D97E (DFÀEULQRJHQLPDJHGE\VFDQQLQJHOHFWURQPLFURVFRS\
Notes:0DJQLÀFDWLRQVA, D, 5,000rB, E, 25,000rC, F, 50,000r.
Abbreviation: WT, wild-type.
WT + 20% erythrocytes D97E + 20% erythrocytes
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Figure 5 'LDPHWHU RI ÀEHUV IURP :7 RU '( ÀEULQ FORWV LQ WKH DEVHQFH RU
presence of erythrocytes.
Notes: 'DWD DUH SUHVHQWHG DV D ER[DQGZKLVNHUV SORW )LEHU GLDPHWHUV ZHUH
PHDVXUHG IURP  UDQGRP ÀEHUV IURP HDFK FRQGLWLRQ LPDJHG ZLWK r 
PDJQLÀFDWLRQp0.0001).
Abbreviation: WT, wild-type.
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would be important to test the binding between the fibrinogen 
variants and erythrocytes in vivo, in order to develop new 
therapeutic approaches to treat fibrinogen-driven erythrocyte 
hyperaggregation.
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